• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    SC 13G/A 1 cah13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) CARDINAL HEALTH INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 14149Y108 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 2,020,533 6. Shared Voting Power* 0 7. Sole Dispositive Power* 4,994,087 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,994,087 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 1.9% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: CARDINAL HEALTH INC Item 1(b) Address of Issuer's Principal Executive Offices: 7000 CARDINAL PLACE, DUBLIN, OHIO 43017 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 14149Y108 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022
    Get the next $CAH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    12/4/2024$139.00Outperform
    Mizuho
    2/26/2024$125.00Outperform
    Leerink Partners
    More analyst ratings

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cardinal Health upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

      6/3/25 7:24:57 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health upgraded by Jefferies with a new price target

      Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

      2/5/25 7:09:45 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health upgraded by TD Cowen with a new price target

      TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously

      1/8/25 7:36:58 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • NYSE Content Advisory: Pre-Market update + Voyager, Ategrity pop double digits in debuts

      NEW YORK, June 12, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on June 12th Stocks are down fractionally this morning after the S&P 500 ended a three-day win streak yesterday. The major index is about 2% from its record.Amid the market momentum, Voyager Technologies (NYSE:VOYG) and Ategrity (NYSE: ASIC) popped double digits in their debuts yesterday. Voyager is a $3.1 billion space and defense company. Ategrity is an insurer valued at about $1.2 billio

      6/12/25 8:55:00 AM ET
      $CAH
      $ICE
      Other Pharmaceuticals
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Cardinal Health Details Momentum and Updated Long-Term Value Creation Plans at Investor Day

      Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to $8.201Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to $9.30 (13% growth at the mid-points)2Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY283Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth3,4Raising long-term target for Other profit to ~10% normalized growth3,4,5Updating GMPD long-term target to $50M+ of profit growth per year after FY26Expecting at least $10B in total adjusted free cash flow over next three yearsRaising baseline share repurchase plans to at least $750M per yearCompany reiterating strateg

      6/12/25 6:45:00 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ramakrishna Sudhakar was granted 1,049 shares (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      3/18/25 4:24:07 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Director Musslewhite Robert W was granted 1,049 shares (SEC Form 4)

      4 - CARDINAL HEALTH INC (0000721371) (Issuer)

      3/18/25 4:20:20 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • New insider Ramakrishna Sudhakar claimed no ownership of stock in the company (SEC Form 3)

      3 - CARDINAL HEALTH INC (0000721371) (Issuer)

      3/11/25 4:11:05 PM ET
      $CAH
      Other Pharmaceuticals
      Health Care

    $CAH
    SEC Filings

    See more
    • SEC Form 11-K filed by Cardinal Health Inc.

      11-K - CARDINAL HEALTH INC (0000721371) (Filer)

      6/20/25 8:32:15 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • SEC Form 11-K filed by Cardinal Health Inc.

      11-K - CARDINAL HEALTH INC (0000721371) (Filer)

      6/20/25 8:31:24 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care
    • Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CARDINAL HEALTH INC (0000721371) (Filer)

      6/12/25 6:47:01 AM ET
      $CAH
      Other Pharmaceuticals
      Health Care